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of all examination procedures. Bypass and repair of ves-
sel procedures gradually rose throughout the ten years
after initial diagnosis, while amputations and skin grafts
remained relatively constant. Procedures involving arteri-
ography rose until year 5 and then tapered off, while uti-
lization of ultrasonography rose in year 7 and tapered
off. The Point Prevalence of inpatient confirmed PAD
was 2.185/100, and the incidence per 1000 patients for
1993, 1994, and 1995 was 1.09, 1.10, and 1.03 respec-
tively. CONCLUSION: The results of this research pro-
vide a foundation for understanding the ten-year trends
associated with PAD-related inpatient procedural care
utilization. These results suggest that PAD-related studies
should consider the progression of the disease past the 5th
year after the initial inpatient visit for PAD when measur-
ing a change in inpatient procedural outcomes.
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TEN-YEAR COSTS ASSOCIATED WITH 
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INPATIENT PROCEDURES IN THE 
DEPARTMENT OF DEFENSE
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OBJECTIVE: The objective of this study was to explore
the trends associated with inpatient procedural medical
care costs the first ten years after initial inpatient confir-
mation of peripheral arterial disease (PAD). METHODS:
A retrospective review of the computer records of all the
beneficiaries of the Department of Defense health care
system was conducted, and over 8000 subjects with an
initial inpatient confirmation of PAD between 1/1/80 and
12/31/85 were reviewed for ten years following the initial
visit. 1997 Medicare 50th percentile reimbursement costs
for PAD related procedures were collected and used in
the analysis. Opportunity costs associated with the inpa-
tient procedures performed were also calculated by utiliz-
ing the Bureau of Labor and Statistic’s hospital services
price index, and future value calculations. RESULTS:
Costs for PAD-related invasive procedures rose gradually
over the ten years after initial diagnosis, while the cost of
examination procedures was highest in the 1st, 5th, and
10th years. Invasive procedures made up 85.5% of the to-
tal ten-year procedural costs, with 10 specific ICD-9-CM
codes accounting for 90% of those costs. Four examina-
tion procedures represented 90% of all examination pro-
cedure costs. Procedures involving vascular bypass had
the highest aggregate costs associated with invasive pro-
cedures, and procedures involving arteriography had the
highest aggregate costs associated with examination pro-
cedures. The institution’s opportunity costs were over
one quarter a million 1997 US dollars at a 10 percent
investment rate. CONCLUSION: The results of this re-
search provide a foundation for understanding the ten-
year trends associated with PAD-related inpatient proce-
dural costs. These results suggest that reducing procedures
involving bypass and arteriography would have the
greatest impact on PAD-related procedural costs.
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Recent efforts to limit health care cost increases have fo-
cused on prescription drugs. Although millions of surgi-
cal procedures are performed in the US each year, limited
information is available about perioperative costs in-
curred by persons undergoing surgery. These types of
data are expected to be important to clinicians and deci-
sion-makers as financial pressure increases to define, un-
derstand, and rationalize medical costs. OBJECTIVES:
This pilot study identified the costs associated with inpa-
tient hospitalization after common abdominal or ortho-
pedic surgeries. METHODS: Total costs from admission
until discharge were identified using the hospital perspec-
tive for persons undergoing total abdominal hysterec-
tomy (TAH), or total joint (hip or knee) replacement
(TJR) between August and November 1999. RESULTS:
Patient’s average age was 53.0 years for all patients, 43.7
years for TAH, and 59.1 years for TJR. More than 70%
of participants had private insurance. Average length of
stay was 3.6 days overall, 3.2 days for TAH, and 4.3
days for TJR. Mean total costs were $6596 for all per-
sons (n  8), $5495 for TAH (n  5), and $8431 for TJR
(n  3). Routine room and operating room costs ac-
counted for 72.5%, 76.3%, and 68.3% of the total,
TAH, and TJR costs, respectively. Pharmacy costs ac-
counted for 4.4% of total costs, 5.9% of TAH costs, and
2.8% of TJR costs. CONCLUSIONS: Most of the costs
incurred during the perioperative period are related to
the surgical procedure and per diem costs. Efforts to re-
strict pharmacy costs are unlikely to significantly affect
total costs.
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Clinical practice guidelines are advocating the use of pri-
mary repair (PR) for treating a penetrating intra-perito-
neal colon injury when clinically appropriate. OBJEC-
TIVE: To estimate the difference in hospital costs in
treating penetrating colon injuries by PR versus diverting
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colostomy (DC). METHODS: Patient-level data from
1996/1997 California and Massachusetts discharge data-
bases were examined. Relevant cases, identified by unique
patient identification, ICD9 diagnosis, procedure and
E-codes were divided into the two surgical groups. Costs
(excluding physician costs) of initial hospitalization and
readmission for colostomy closure were calculated. Sta-
tistical analyses were performed using chi-square and
Wilcoxon tests for: number of colon injuries; co-existing
intra-abdominal injuries; and complications. Cost esti-
mates, adjusted for medical inflation and cost-to-charge
ratios, are reported in 1999 US $. RESULTS: Of the 597
patients identified, 489 (83%) had a PR. The mean initial
length-of-stay was longer for the colostomy group (13.5
versus 10.4 days). The mean total cost of the initial stay
was $32,800 and $46,100 for the PR and DC groups, re-
spectively. Colostomy patients were referred for home
health care (HHC) four times more often. The mean re-
admission cost for colostomy closure was $15,400, re-
sulting in a combined mean hospital cost of $61,500 for
the DC group. No significant statistical differences in
number of colon injuries, other intra-abdominal injuries
or complications were revealed. CONCLUSIONS: The
cost of managing a colon injury with a colostomy is al-
most twice as much as one managed with PR. This cost
difference estimate is conservative as it does not include
physician, HHC, colostomy care or supply costs, which
would increase the overall cost of the DC approach. Eco-
nomic, as well as clinical consequences exist regarding
choice of surgical repair.
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Purified perfluoro-n-octane (PFnO) was approved for use
as an intraoperative vitreous substitute during retinal de-
tachment surgery in 1996. This new technology is associ-
ated with improved surgical outcomes. While PFnO is
used increasingly in the hospital setting, usage in ambula-
tory surgical centers (ASC) is infrequent, likely due to
current Medicare reimbursement. Health Care Financing
Administration’s (HCFA) proposal to lower ASC reim-
bursement rates based on pre-1996 data threatens to fur-
ther discourage PFnO use. OBJECTIVE: To investigate
the economic impact of PFnO during retinal detachment
surgery, and to determine whether this impact justifies
additional ASC Medicare reimbursement. METHODS:
An economic model was developed based on retinal de-
tachment surgery success rates published in the literature
and 1997 Medicare Part B Extract and Summary System
data from HCFA. This model includes a yearly projection
from 1998–2002 to estimate HCFA costs over 5 years if
PFnO is used. HCFA’s recently proposed reimbursement
fee is used to estimate Medicare-related costs to HCFA
for retinal detachment repair using PFnO. RESULTS:
Retinal detachment surgery success rates indicate that
PFnO use is associated with 133,175 fewer retinal de-
tachment reoperations required over five years, corre-
sponding to a cost savings exceeding $268M. A recom-
mended additional reimbursement of $230.00 per surgery
would be associated with a net cost savings to HCFA of
$75.6M over five years. An additional reimbursement of
$320.30 per surgery for PFnO would be budget neutral.
CONCLUSIONS: PFnO represents a new technology as-
sociated with improved surgical outcomes and reduced
health care costs. Because current reimbursement policies
may discourage the use of PFnO in ASCs, an additional
reimbursement of $230.00 per surgery is recommended
when PFnO is used.
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The use of epoetin alpha in the community hospital has
dramatically improved patient outcomes while at the
same time has become the most expensive medication on
the hospital formulary. Significant savings can be achieved
and patient care improved by the development and im-
plementation of guidelines for the use and distribution of
epoetin alpha. OBJECTIVE: The goal of this study is to
use cost-minimization analysis to find ways the commu-
nity hospital can reduce the cost of treating patients with
epoetin alpha while at the same time develop sound
health economic policies which will insure the best possi-
ble care for their patients. To develop a multi-disciplinary
model of care which will assist the clinical pharmacist in
monitoring patients being treated with epoetin alpha.
METHODS: Data was collected pertaining to the pur-
chase, distribution, use and non-use of epoetin alpha at
John T. Mather Memorial Hospital for two one-week pe-
riods. Cost-minimization analysis was utilized to find the
least expensive method of acquisition, distribution and
dispensing of epoetin alpha. RESULTS: In the two weeks
of the study, 155 doses of epoetin alpha were dispensed
to 79 patients at a cost of $22,631.55. A total of 44 doses
were dispensed and not utilized by the patients at a cost
of $9484.80. Of the 79 patients studied, 11% of the pa-
tients had hematocrit levels that did not warrant use of
epoetin alpha and 45% of the patients showed no indi-
cated need for the drug totaling $8579.78. CONCLU-
SION: The utilization of pharmacoeconomics and clini-
cal pharmacists in the community hospital will result in
the development of health care management policies that
will not only provide better patient care, but greater eco-
nomic benefits as well.
